AbbVie is reconsidering its takeover of Shire, putting it on track to become the biggest deal to be torpedoed by a crackdown on tax inversions.
AbbVie is reconsidering its takeover of Shire, putting it on track to become the biggest deal to be torpedoed by a crackdown on tax inversions.